196 related articles for article (PubMed ID: 2560421)
21. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
Chang SC; Hsu LY; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
[TBL] [Abstract][Full Text] [Related]
22. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
23. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
Jones RN; Sutton LD; Cantrell HF; Lankford RB
Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
[TBL] [Abstract][Full Text] [Related]
24. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
26. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
28. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
Wüst J; Hardegger U
Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
[TBL] [Abstract][Full Text] [Related]
30. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Schaumann R; Funke M; Janssen E; Rodloff AC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
[TBL] [Abstract][Full Text] [Related]
31. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
32. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Aldridge KE
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
Liebowitz LD; Klugman KP
S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
[TBL] [Abstract][Full Text] [Related]
34. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
Murray PR; Cantrell HF; Lankford RB
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
[TBL] [Abstract][Full Text] [Related]
35. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1990 Aug; 34(8):1546-50. PubMed ID: 2221864
[TBL] [Abstract][Full Text] [Related]
36. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
[TBL] [Abstract][Full Text] [Related]
37. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
Reeves DS; Holt HA; Bywater MJ; MacGowan AP
J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
Van der Auwera P; Duchateau V; Lambert C; Husson M; Kinzig M; Sörgel F
Antimicrob Agents Chemother; 1993 Sep; 37(9):1860-8. PubMed ID: 8239597
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]